Pharmacosmos Acquires G1 Therapeutics

MorphoSys Acquires Constellation Pharmaceuticals for $1.7B

June 2, 2021

Biotechnology

MorphoSys AG has agreed to acquire Constellation Pharmaceuticals for $34.00 per share in cash, valuing the transaction at approximately $1.7 billion. The deal strengthens MorphoSys' hematology-oncology pipeline by adding Constellation's mid- to late-stage candidates (pelabresib/CPI-0610 and CPI-0209) and is supported by a strategic funding partnership with Royalty Pharma that provides significant upfront and milestone funding.

Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics

August 31, 2020

Biotechnology

Ionis Pharmaceuticals agreed to acquire the approximately 24% of Akcea Therapeutics it does not already own for $18.15 per share in cash, implying a fully diluted transaction value of about $500 million. The deal will be executed via a tender offer followed by a second-step merger, and Ionis expects to complete the transaction in Q4 2020 to consolidate Akcea's pipeline, commercial products and cash while realizing cost synergies.

Pharmacosmos A/S Acquires AbFero Pharmaceuticals, Inc.

November 11, 2021

Pharmaceuticals

Pharmacosmos A/S (Pharmacosmos Group) has agreed to acquire all assets of Boston-based clinical-stage AbFero Pharmaceuticals, Inc. under a share purchase agreement for up to $225 million including upfront, milestone, and royalty components. The acquisition adds AbFero’s SP-420 iron chelation program to Pharmacosmos’ iron-metabolism-focused R&D and commercial capabilities to accelerate development and commercialization for transfusional iron overload and related indications.

Galecto Inc. Merges with San Diego-based PharmAkea, Inc.

January 9, 2020

Pharmaceuticals

Copenhagen-headquartered Galecto Inc. (a Novo Seeds portfolio company) has merged with San Diego-based PharmAkea, Inc. The combined clinical-stage company will retain the Galecto name, be incorporated in the United States, and combine complementary pipelines in fibrosis and oncology to accelerate development of small-molecule and galectin-targeting therapeutics.

Supernus Pharmaceuticals Acquires Adamas Pharmaceuticals

October 11, 2021

Pharmaceuticals

Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals in a cash tender offer valued at approximately $400 million upfront plus up to $50 million in contingent value rights, for total consideration of about $450 million. The acquisition gives Supernus two marketed CNS products (GOCOVRI and Osmolex ER), diversifies its Parkinson’s disease portfolio and is expected to be accretive with material synergies in 2022.

Gilead Sciences To Acquire Arcellx for $7.8 Billion to Strengthen CAR T-Cell Portfolio

February 21, 2026

Biotechnology

Gilead Sciences entered into a definitive agreement to acquire Arcellx, Inc. for $115 per share in cash plus a contingent value right of $5 per share, implying an equity value of about $7.8 billion. The deal is designed to give Gilead full control of Arcellx’s anito-cel (anito-cabtagene autoleucel) BCMA-directed CAR T therapy, eliminating profit-sharing and related payments while accelerating development and commercialization.